|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SOWAHC |
Gene summary for SOWAHC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SOWAHC | Gene ID | 65124 |
| Gene name | sosondowah ankyrin repeat domain family member C | |
| Gene Alias | ANKRD57 | |
| Cytomap | 2q13 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q53LP3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65124 | SOWAHC | P65T-E | Human | Esophagus | ESCC | 4.99e-23 | -4.14e-01 | 0.0978 |
| 65124 | SOWAHC | P74T-E | Human | Esophagus | ESCC | 8.59e-03 | -1.69e-01 | 0.1479 |
| 65124 | SOWAHC | P75T-E | Human | Esophagus | ESCC | 1.54e-19 | -2.70e-01 | 0.1125 |
| 65124 | SOWAHC | P76T-E | Human | Esophagus | ESCC | 8.58e-25 | -5.12e-01 | 0.1207 |
| 65124 | SOWAHC | P79T-E | Human | Esophagus | ESCC | 2.01e-09 | -3.83e-01 | 0.1154 |
| 65124 | SOWAHC | P80T-E | Human | Esophagus | ESCC | 9.36e-15 | -7.39e-02 | 0.155 |
| 65124 | SOWAHC | P82T-E | Human | Esophagus | ESCC | 3.29e-06 | -9.58e-02 | 0.1072 |
| 65124 | SOWAHC | P83T-E | Human | Esophagus | ESCC | 1.39e-07 | 1.63e-02 | 0.1738 |
| 65124 | SOWAHC | P84T-E | Human | Esophagus | ESCC | 4.53e-02 | -3.99e-01 | 0.0933 |
| 65124 | SOWAHC | P89T-E | Human | Esophagus | ESCC | 2.95e-03 | -2.94e-01 | 0.1752 |
| 65124 | SOWAHC | P107T-E | Human | Esophagus | ESCC | 1.29e-09 | 5.47e-01 | 0.171 |
| 65124 | SOWAHC | P127T-E | Human | Esophagus | ESCC | 1.19e-07 | -6.51e-02 | 0.0826 |
| 65124 | SOWAHC | P130T-E | Human | Esophagus | ESCC | 5.60e-09 | 5.28e-01 | 0.1676 |
| 65124 | SOWAHC | HCC1_Meng | Human | Liver | HCC | 1.89e-58 | 1.79e-01 | 0.0246 |
| 65124 | SOWAHC | HCC2_Meng | Human | Liver | HCC | 6.53e-21 | 1.85e-01 | 0.0107 |
| 65124 | SOWAHC | cirrhotic2 | Human | Liver | Cirrhotic | 3.14e-02 | 5.69e-02 | 0.0201 |
| 65124 | SOWAHC | HCC1 | Human | Liver | HCC | 3.63e-04 | 3.28e+00 | 0.5336 |
| 65124 | SOWAHC | HCC2 | Human | Liver | HCC | 5.07e-27 | 4.67e+00 | 0.5341 |
| 65124 | SOWAHC | HCC5 | Human | Liver | HCC | 4.73e-02 | 8.72e-01 | 0.4932 |
| 65124 | SOWAHC | Pt13.b | Human | Liver | HCC | 7.73e-04 | 9.90e-02 | 0.0251 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOWAHC | insertion | Nonsense_Mutation | novel | c.1447_1448insTGCTCAAGCTTGTTTGGATACGTAATCTATGA | p.His483LeufsTer11 | p.H483Lfs*11 | Q53LP3 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| SOWAHC | SNV | Missense_Mutation | c.1358N>T | p.Ala453Val | p.A453V | Q53LP3 | protein_coding | tolerated(0.24) | benign(0.006) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SOWAHC | deletion | Frame_Shift_Del | c.1577delN | p.Ter526%3D | p.*526%3D | Q53LP3 | protein_coding | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| SOWAHC | deletion | Frame_Shift_Del | rs766957308 | c.1493delN | p.Glu500ArgfsTer18 | p.E500Rfs*18 | Q53LP3 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| SOWAHC | deletion | Frame_Shift_Del | rs766957308 | c.1493delN | p.Glu500ArgfsTer18 | p.E500Rfs*18 | Q53LP3 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SOWAHC | SNV | Missense_Mutation | novel | c.1007N>A | p.Ala336Asp | p.A336D | Q53LP3 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | novel | c.1252N>A | p.Val418Met | p.V418M | Q53LP3 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | novel | c.1189C>A | p.Leu397Met | p.L397M | Q53LP3 | protein_coding | tolerated(0.07) | probably_damaging(0.942) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | c.1373G>A | p.Arg458His | p.R458H | Q53LP3 | protein_coding | deleterious(0.01) | possibly_damaging(0.899) | TCGA-AX-A064-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SOWAHC | SNV | Missense_Mutation | novel | c.613N>A | p.Leu205Ile | p.L205I | Q53LP3 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |